Firm Events
District Court vs. PTAB: Strategic Forum Selection in Life Sciences Patent Disputes
December 10, 2026 | 12:00 PM – 1:00 PM ET
Effective March 18, 2026, officers and directors of foreign private issuers that have securities listed on a U.S. securities exchange or registered with the Securities and Exchange Commission (SEC) (for purposes of this alert, reporting FPIs) will be subject to insider reporting under Section 16(a) of the Securities Exchange Act of 1934. Officers and directors of reporting FPIs will be required to report their holdings of, and transactions in, company equity securities, beginning March 18, 2026. For further details, please see our prior alerts dated December 23, 2025, and February 2, 2026, regarding these new requirements.
The SEC has authority to exempt any person, security, or transaction from Section 16(a) insider reporting if the SEC determines that the laws of a foreign jurisdiction apply “substantially similar requirements” to that person, security, or transaction. Although the SEC stated that it may consider granting such exemptive relief in a separate rulemaking or order, as of the date of this alert, the SEC has not provided any exemptive relief.
On February 27, 2026, the SEC adopted final amendments to rules and forms to reflect the requirements of the Holding Foreign Insiders Accountable Act (HFIAA). The SEC’s final amendments revise the following rules and forms to reflect the changes made by the HFIAA:
With the effective date quickly approaching, reporting FPIs should continue preparing to assist their officers and directors with insider reporting, including, but not limited to, coordinating with counsel and administrators to prepare timely Section 16 filings beginning March 18, 2026. If you have not already done so, we recommend that reporting FPIs confirm or obtain EDGAR Next enrollment, and EDGAR codes, for officers and directors subject to insider reporting as soon as possible, as that process of obtaining these codes can take up to a few weeks.
This just in
Firm Events
District Court vs. PTAB: Strategic Forum Selection in Life Sciences Patent Disputes
December 10, 2026 | 12:00 PM – 1:00 PM ET
Speaking Engagements
Performance on Trial: The Construction Manager’s Standard of Care Examined from All Angles
December 2, 2026 | 4:15 PM – 5:30 PM ET
The Hyatt Regency Huntington Beach
Huntington Beach, CA
Speaking Engagements
ACI’s 31st Annual Conference on Drug & Medical Device Litigation – 2026
December 2 – 3, 2026
New York Marriott Marquis
1535 Broadway, New York, NY 10036
Speaking Engagements
Fundamentals of Investment Adviser Regulation 2026
November 19, 2026 | 2:30 PM – 3:30 PM ET
PLI New York
1177 Avenue of the Americas, Entrance on 45th Street, New York, NY 10036